Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTB Connect Biopharma Holdings Ltd.

Pre-Mkt 04-14 05:22:47 EDT

2.83

+0.01

+0.35%

High3.10	Low2.69	Vol397.02K
Open2.81	D1 Closing2.82	Amplitude14.54%
Mkt Cap159.96M	Tradable Cap37.34M	Total Shares56.52M
T/O1.15M	T/O Rate3.01%	Tradable Shares13.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTB","market":"US","secType":"STK","nameCN":"Connect Biopharma Holdings Ltd.","latestPrice":2.83,"timestamp":1776110400000,"preClose":2.82,"halted":0,"volume":397022,"delay":0,"changeRate":0.0035460992907802237,"floatShares":13195800,"shares":56521282,"eps":-1,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"04-14 05:22:47 EDT","open":2.81,"high":3.1,"low":2.69,"amount":1154912.0650184,"amplitude":0.14539,"askPrice":2.95,"askSize":25,"bidPrice":2.75,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-1,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776173400000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1616126400000,"exchange":"NASDAQ","adjPreClose":2.83,"postHourTrading":{"tag":"盘后","latestPrice":2.79,"preClose":2.83,"latestTime":"18:43 EDT","volume":555,"amount":1548.57,"timestamp":1776120192058,"change":-0.04,"changeRate":-0.014134,"amplitude":0.014134},"volumeRatio":0.9878412347273218,"impliedVol":0.9073,"impliedVolPercentile":0.1727},"requestUrl":"/m/hq/s/CNTB","defaultTab":"news","newsList":[{"id":"2625594833","title":"Analysts Offer Insights on Healthcare Companies: Alpha Cognition Inc (ACOG), Insmed (INSM) and Connect Biopharma Holdings (CNTB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625594833","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625594833?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:30","pubTimestamp":1775644248,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alpha Cognition Inc (ACOG), Insmed (INSM) and Connec...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alpha-cognition-inc-acog-insmed-insm-and-connect-biopharma-holdings-cntb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alpha-cognition-inc-acog-insmed-insm-and-connect-biopharma-holdings-cntb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU0053671581.USD","LU0109394709.USD","BK4588","HCSG","CNTB","ACOG","LU0029874061.USD","LU0320765992.SGD","XBI","XLV","BK4585","BK4139","BK4137","LU0889565916.HKD","INSM","LABU","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624522143","title":"Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2624522143","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624522143?lang=en_us&edition=fundamental","pubTime":"2026-04-02 12:14","pubTimestamp":1775103240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 00:14 ET (04:14 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624541590","title":"Connect Biopharma director James Huang acquires $4 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2624541590","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624541590?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:31","pubTimestamp":1775075497,"startTime":"0","endTime":"0","summary":"Connect Biopharma director James Huang reported purchase of 1,160,000 ordinary shares at $3.45.Indirect beneficial ownership rose to 13,160,000 ordinary shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL9zKrpC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Connect Biopharma director James Huang acquires $4 million common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518475","title":"Connect Biopharma Holdings Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518475?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:58","pubTimestamp":1774997906,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings Ltd reports results for the quarter ended December 31 - Earnings SummaryConnect Biopharma Holdings Ltd CNTB.OQ reported a quarterly adjusted loss of 27 fen per share for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J2KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624312555","title":"Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2624312555","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624312555?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:30","pubTimestamp":1774992607,"startTime":"0","endTime":"0","summary":"Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.30) by 10 percent. This is a 68.75 percent decrease over losses of $(0.16) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51587159/connect-biopharma-hldgs-q4-eps-0-27-beats-0-30-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Connect Biopharma Hldgs Q4 EPS $(0.27) Beats $(0.30) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624447537","title":"Connect Biopharma FY25 net loss widens to $55.5 million; cash, investments fall to $44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624447537","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624447537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:12","pubTimestamp":1774987930,"startTime":"0","endTime":"0","summary":"Connect Biopharma posted a net loss of $56 million, or  per share, for full-year 2025.Research and development expense climbed to $38 million due to higher rademikibart development costs tied to initiation of Phase 2 Seabreeze STAT asthma and COPD studies.March highlights included positive Phase 1 topline data for IV rademikibart in asthma or COPD, showing rapid FEV1 improvement as early as 15 minutes post-dose.Cash, cash equivalents and short-term investments totaled $44 million; Connect expects funds, including net proceeds from a $20 million private placement, to support operations into second half of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLb3nWSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624676537","title":"Press Release: Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624676537","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624676537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:05","pubTimestamp":1774987500,"startTime":"0","endTime":"0","summary":"-- Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD --. -- Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD --. -- Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies mid-2026 --. -- Entered into a securities purchase agreement for $20.2 million equity financing extending our cash runway into second half of 2027 --. SAN DIEGO, March 31, 2026  -- Connect Biopharma Holdings Limited  , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported financial results for the three and twelve months ended December 31, 2025, and provided a business update.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4132","BK4139","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623587703","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623587703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623587703?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:50","pubTimestamp":1774965030,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNY), Milestone Pharmaceuticals (MIST) and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanofi-sny-milestone-pharmaceuticals-mist-and-connect-biopharma-holdings-cntb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-sanofi-sny-milestone-pharmaceuticals-mist-and-connect-biopharma-holdings-cntb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB","IE00BFXG1179.USD","BK4588","BK4585","LABU","SNY","BK4581","HCSG","LU0128526141.USD","BK4007","BK4139","LU0029874061.USD","MIST","XLV","BK4137","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623588946","title":"Connect Biopharma Price Target Maintained With a $10.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2623588946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623588946?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:39","pubTimestamp":1774953540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CNTB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 06:39 ET (10:39 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623732599","title":"Connect Biopharma Shares Decline on Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2623732599","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623732599?lang=en_us&edition=fundamental","pubTime":"2026-03-31 03:04","pubTimestamp":1774897440,"startTime":"0","endTime":"0","summary":"Shares of Connect Biopharma slid after the company said it would sell shares in a private placement for expected gross proceeds of about $20.2 million.The stock declined 18%, to $2.82, midday Monday. Shares have more than quadrupled over the past year.The biopharmaceutical company said it entered an agreement with a group of institutional investors to sell 6.1 million shares at $3.25 apiece in a private placement. The price represents a discount to the stock's last closing price of $3.45.The placement was led by Panacea Venture, Connect Biopharma's largest current investor, with participation from other U.S.-based healthcare focused investors, the company said.The company also separately disclosed results from a Phase 3 study for a potential treatment for moderate-to-severe atopic dermatitis. The drug, called Rademikibart, achieved efficacy across all key endpoints through 52 weeks, the company said.Additionally, topline data from a Phase 1 study evaluating intravenous Rademikibart in ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Connect Biopharma Shares Decline on Private Placement","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623342665","title":"BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar","url":"https://stock-news.laohu8.com/highlight/detail?id=2623342665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623342665?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:53","pubTimestamp":1774886000,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, KezarWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL6N40I13J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HL","AA","FLEX","PWR","SR","XOMX","BIIB","ALV","SSII","CL","IDYA","APO","GPI","XOMO","EXPE","MMYT","NEMG","KKR","CENX","INSM","ZYME","ALK","CRWD","CNTB","SOC","CG","NEM","VRDN","UTHR","BFLY","KALU","BX","KZR","CART","NVAX","CDE","GEVO","ADNT","DVN","SYY","GM","RARE","BSX","PUMP","ADMA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623456183","title":"Analysts Conflicted on These Healthcare Names: Connect Biopharma Holdings (CNTB), Neumora Therapeutics, Inc. (NMRA) and Merck & Company (MRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623456183","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623456183?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:40","pubTimestamp":1774878027,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Connect Biopharma Holdings (CNTB), Neumora Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-connect-biopharma-holdings-cntb-neumora-therapeutics-inc-nmra-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-connect-biopharma-holdings-cntb-neumora-therapeutics-inc-nmra-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4007","IE00BJT1NW94.SGD","LU0070302665.USD","LU2089984988.USD","LU1023059063.AUD","LU0234572021.USD","LU0208291251.USD","LU1057294990.SGD","SG9999014542.SGD","LU1066051498.USD","SG9999014575.USD","SG9999001176.USD","LU2361044949.HKD","LU1061106388.HKD","SG9999001440.SGD","BK4550","LU0058720904.USD","LU1066051225.USD","LU2023250504.SGD","IE0009355771.USD","CNTB","LU1037948897.HKD","IE00BFTCPJ56.SGD","LU0203345920.USD","LU0320765646.SGD","LU1941712348.USD","LU1983299246.USD","LU0320765489.SGD","BK4139","LU1116320737.USD","LU1974910355.USD","LU1037948541.HKD","IE00B4R5TH58.HKD","LU1989772923.USD","LU0477156953.USD","LU2461242641.AUD","LU0965508806.USD","LU0985320562.USD","SG9999015358.SGD","BK4585","LU0965509010.AUD","LU0868494708.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU0265550946.USD","LU0130517989.USD","LU2361045086.USD","BK4559","LU0965509101.SGD","SGXZ57979304.SGD","LU2125154778.USD","BK4137","LU1929549753.HKD","LU0122379950.USD","BK4533","NMRA","LU0238689110.USD","SG9999014567.USD","LU1162221912.USD","LU1093756168.USD","SG9999015341.SGD","LU0203347892.USD","BK4581","LU1941712264.USD","LU0211331839.USD","SG9999001176.SGD","SG9999013999.USD","LU1917777945.USD","IE00B2B36J28.USD","LU0098860793.USD","LU1201861249.SGD","LU2360032135.SGD","SG9999002232.USD","LABU","IE00BN8TJ469.HKD","LU0130102774.USD","LU2106854487.HKD","LU0861579265.USD","BK4516","LU2468319806.SGD","IE00B1BXHZ80.USD","LU2361044865.SGD","LU1699723380.USD","LU1066051811.HKD","LU1291159041.SGD","IE000M9KFDE8.USD","LU0029874061.USD","LU1934455863.HKD","MRK","LU2112291526.USD","IE00BLSP4452.SGD","LU2125154935.USD","XBI","LU1585245621.USD","LU0006306889.USD","LU1093756325.SGD","LU1116320901.HKD","LU0266013472.USD","LU2324357040.USD","LU1989772840.SGD","LU0942090050.USD","LU1035773651.USD","LU1571399168.USD","LU1069347547.HKD","LU0965509283.SGD","LU0289739699.SGD","SG9999002224.SGD","SG9999014559.SGD","BK4588","LU0128526141.USD","LU2023250843.SGD","LU0980610538.SGD","LU0265550359.USD","IE00BLSP4239.USD","IE0002141913.USD","LU0432979614.USD","LU0648001328.SGD","LU0868494617.USD","LU1934455194.USD","LU0106261372.USD","LU1934455277.USD","LU1989771016.USD","LU1066053197.SGD","IE00BBT3K403.USD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345388","title":"Connect Biopharma Announces Positive Topline Data From Its Phase 1 Study Of Intravenous (Iv) Rademikibart In Patients With Asthma Or Copd","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345388","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345388?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:34","pubTimestamp":1774877664,"startTime":"0","endTime":"0","summary":"March 30 (Reuters) - Connect Biopharma Holdings Ltd ::*CONNECT BIOPHARMA ANNOUNCES POSITIVE TOPLINE DATA FROM ITS PHASE 1 STUDY OF INTRAVENOUS (IV) RADEMIKIBART IN PATIENTS WITH ASTHMA OR COPD*CONNECT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nRSD22z7kv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623343620","title":"BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2623343620","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623343620?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:20","pubTimestamp":1774876843,"startTime":"0","endTime":"0","summary":"BRIEF-Rademikibart Demonstrates Best-In-Class Potential In Phase 3 Atopic Dermatitis StudyMarch 30 (Reuters) - Connect Biopharma Holdings Ltd CNTB.O:RADEMIKIBART DEMONSTRATES BEST-IN-CLASS POTENTIAL I","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nFWN40I0MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623343857","title":"BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike","url":"https://stock-news.laohu8.com/highlight/detail?id=2623343857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623343857?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:12","pubTimestamp":1774876323,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrikeWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call n","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL6N40I0O0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UTHR","HLXX","XOMZ","DVN","IE00B7KXQ091.USD","LU2237438978.USD","CDE","ALK","GPI","NEMG","CRWL","PWR","VRDN","NVAX","HL","GM","INSM","ZYME","EXPE","XOMO","EVTL","NEM","NWMX","LU0640476718.USD","ADNT","KALU","SOC","BFLY","CENX","SR","BSX","CNTB","CL","AA","ADMA","CART","CRWD","XOMX","AU","SYY","LU0109394709.USD","IDYA","RARE","ALV","BIIB"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2623764317","title":"Connect Biopharma Highlights Positive Rademikibart Respiratory Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2623764317","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623764317?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:09","pubTimestamp":1774872584,"startTime":"0","endTime":"0","summary":"Connect Biopharma Holdings ( ($CNTB) ) has shared an update. On March 29, 2026, Connect Biopharma entered into a securities purchase agreement for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-highlights-positive-rademikibart-respiratory-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/connect-biopharma-highlights-positive-rademikibart-respiratory-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623128303","title":"BUZZ-Connect Biopharma rises as eczema drug shows lasting benefit in China study","url":"https://stock-news.laohu8.com/highlight/detail?id=2623128303","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623128303?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:42","pubTimestamp":1774870938,"startTime":"0","endTime":"0","summary":"BUZZ-Connect Biopharma rises as eczema drug shows lasting benefit in China study** Shares of biotech firm Connect Biopharma CNTB.O rise 7.9% to $3.72 premarket** Co says its experimental drug rademikibart showed strong, lasting benefit in a yearlong latestage study in China in people with moderatetosevere eczema, a common inflammatory skin disease** Says nearly 90% of patients in the 52week study had clear or almost clear skin, while about 97% saw major reductions in disease severity** Says the drug was well-tolerated, with side effects similar to placebo and low eye inflammation seen with rival treatments** Adds the study was run by its China partner Simcere, which holds Greater China rights and could owe up to $110 million in milestones and royalties** Says rademikibart is not yet approved anywhere and it is seeking partners outside China** CNTB rose about two-fold in 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL4N40I0Z8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623631113","title":"Connect Biopharma says rademikibart hits EASI-75 in 96.6% in Phase 3 AD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623631113","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623631113?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:06","pubTimestamp":1774868764,"startTime":"0","endTime":"0","summary":"Connect Biopharma disclosed Phase 3 52-week RADIANT-AD results for rademikibart in moderate-to-severe atopic dermatitis, already presented March 28 at 2026 American Academy of Dermatology annual meeting.Trial enrolled 259 patients in China, testing rademikibart 300 mg every two weeks versus placebo for 16 weeks, followed by switch to active drug through Week 52.Week 52 efficacy showed 96.6% achieved EASI-75, with 87.1% reaching IGA 0/1.Safety profile was comparable to placebo at 16 weeks, with conjunctivitis rates not differentiated from placebo in induction phase.Company highlighted optionality to pursue atopic dermatitis outside China based on durability through 52 weeks.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6wK0zT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4588","IE00BN0W2T93.GBP","BK4585","LU2210149790.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4112","CNTB","NDAQ","SG9999014021.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623152311","title":"Connect Biopharma says Phase 1 IV rademikibart trial shows rapid FEV1 improvement in asthma, COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2623152311","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623152311?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:05","pubTimestamp":1774868724,"startTime":"0","endTime":"0","summary":"Connect Biopharma reported positive topline preliminary Phase 1 data for intravenous rademikibart in stable asthma or COPD patients.Single 300 mg 2-minute IV push produced FEV1 gains of 100 mL to more than 400 mL as early as 15 minutes post-dose in many patients.Mean FEV1 improvement of about 200 mL to 400 mL was maintained through Day 29 in both cohorts.Study reported no serious adverse events, no severe adverse events, no discontinuations tied to adverse events.Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD remain in recruitment, with topline data expected mid-2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6zvlql:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","CNTB","SG9999014039.USD","IE00BN0W2V16.EUR","BK4139","BK4112","BK4588","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014005.SGD","NDAQ","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311662","title":"Press Release: Connect Biopharma Announces $20.2 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311662","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311662?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:02","pubTimestamp":1774868520,"startTime":"0","endTime":"0","summary":"Funding from new and existing investors extends anticipated cash runway into the second half of 2027. SAN DIEGO, March 30, 2026  -- Connect Biopharma Holdings Limited  , a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of its ordinary shares in a private placement at a price of $3.25 per share with respect to any purchaser that is not owned or controlled by an individual who is an officer, director, employee or consultant of the Company.Connect anticipates the gross proceeds from the private placement will be approximately $20.2 million, before deducting placement agent fees and other offering expenses. The private placement is expected to close on or about March 31, 2026, subject to customary closing conditions.The private placement was led by the Company's largest ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CNTB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.connectbiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0105},{"period":"1month","weight":0.052},{"period":"3month","weight":0.2982},{"period":"6month","weight":0.5134},{"period":"1year","weight":3.528},{"period":"ytd","weight":0.0035}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.028496},{"month":2,"riseRate":0.6,"avgChangeRate":-0.025044},{"month":3,"riseRate":0.4,"avgChangeRate":-0.062942},{"month":4,"riseRate":0.5,"avgChangeRate":-0.001738},{"month":5,"riseRate":0.6,"avgChangeRate":-0.072705},{"month":6,"riseRate":0.8,"avgChangeRate":0.091691},{"month":7,"riseRate":0.4,"avgChangeRate":0.150673},{"month":8,"riseRate":0.8,"avgChangeRate":0.204473},{"month":9,"riseRate":0.2,"avgChangeRate":-0.084295},{"month":10,"riseRate":0.4,"avgChangeRate":0.007717},{"month":11,"riseRate":0.2,"avgChangeRate":-0.108453},{"month":12,"riseRate":1,"avgChangeRate":0.142382}],"exchange":"NASDAQ","name":"Connect Biopharma Holdings Ltd.","nameEN":"Connect Biopharma Holdings Ltd.","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Connect Biopharma Holdings Ltd.(CNTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Connect Biopharma Holdings Ltd.,CNTB,Connect Biopharma Holdings Ltd.股票,Connect Biopharma Holdings Ltd.股票老虎,Connect Biopharma Holdings Ltd.股票老虎国际,Connect Biopharma Holdings Ltd.行情,Connect Biopharma Holdings Ltd.股票行情,Connect Biopharma Holdings Ltd.股价,Connect Biopharma Holdings Ltd.股市,Connect Biopharma Holdings Ltd.股票价格,Connect Biopharma Holdings Ltd.股票交易,Connect Biopharma Holdings Ltd.股票购买,Connect Biopharma Holdings Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Connect Biopharma Holdings Ltd.(CNTB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Connect Biopharma Holdings Ltd.(CNTB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction